Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31703779 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL29155628 | 0.84 | NR1H3 (0.45) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL2079703 | 0.84 | KMT2A (0.57) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL2081137 | 0.84 | KMT2A (0.57) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL27493913 | 0.82 | S100A4 (0.44) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL27584097 | 0.80 | KMT2A (0.41) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL25322071 | 0.79 | NR1H3 (0.50) | ALDH1A1MAPTKMT2AHPGDGAA | |
| SCHEMBL18539802 | 0.79 | CYP3A4 (0.43) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL10323011 | 0.79 | RAB9A (0.57) | ALDH1A1MAPTKMT2AKDM4EHPGD | |
| SCHEMBL25278023 | 0.79 | KMT2A (0.57) | ALDH1A1MAPTKMT2AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640688-A1 | AVERMECTIN DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025215286-A1 | SULFONAMIDES, COMPOSITIONS COMPRISING SAID SULFONAMIDES, METHODS FOR THE PREPARATION OF SAID SULFONAMIDES, AND SAID SULFONAMIDES FOR USE AS MEDICAMENT AND IN A METHOD FOR THE TREATMENT OR PREVENTION OF AN OCULAR DISEASE OR CONDITION, OR IDIOPATHIC INTRACRANIAL HYPERTENSION | ITÄ-SUOMEN YLIOPISTO (FI) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215303-A1 | SULFONAMIDES, COMPOSITIONS COMPRISING SAID SULFONAMIDES, METHODS FOR THE PREPARATION OF SAID SULFONAMIDES, AND SAID SULFONAMIDES FOR USE AS MEDICAMENT AND IN A METHOD FOR THE TREATMENT OR PREVENTION OF AN OCULAR DISEASE OR CONDITION, OR IDIOPATHIC INTRACRANIAL HYPERTENSION | ITÄ-SUOMEN YLIOPISTO (FI) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024135828-A1 | AVERMECTIN DERIVATIVE | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2006086517-A2 | INHIBITORS OF TRANSTHYRETIN AMYLOID FIBRIL FORMATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060178527-A1 | Inhibitors of transthyretin amyloid fibril formation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-08-10 | — | — | US | disclosed |
| US-4596869-A | Pyridinyl and pyrimidinyl derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-06-24 | — | — | US | disclosed |
| US-4582908-A | CHEMICAL INTERMEDIATES OF CEPHALOSPORIN DERIVATIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-15 | — | — | US | disclosed |
| EP-0029998-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-06 | — | — | EP | disclosed |
| US-4493834-A | BACTERICIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-15 | — | — | US | disclosed |
| US-4420477-A | ANTIBIOTICS, BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-13 | — | — | US | disclosed |
| US-4395411-A | ANTIBIOTICS; BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-07-26 | — | — | US | disclosed |
| EP-0029998-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
| US-4267176-A | Amino or acylamino-substituted pyrimidinyl cephalosporanic acid derivatives and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | ALDH1A1 3080/4885MAPT 1/4885KMT2A 2570/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | ALDH1A1 3619/4885MAPT 3633/4885KMT2A 4624/4885 |
| US-20060178527-A1 | Inhibitors of transthyretin amyloid fibril formation | TTR, TTPA, APOB | ALDH1A1 2778/4885MAPT 8/4885KMT2A 3558/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | ALDH1A1 3080/4885MAPT 1/4885KMT2A 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.